Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$9.4 million.

  • Sangamo Therapeutics' Net Cash Flow fell 17937.91% to -$9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year increase of 3651.21%. This contributed to the annual value of -$1.2 million for FY2024, which is 9781.75% up from last year.
  • As of Q3 2025, Sangamo Therapeutics' Net Cash Flow stood at -$9.4 million, which was down 17937.91% from $10.4 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Net Cash Flow peaked at $46.8 million during Q2 2021, and registered a low of -$58.8 million during Q1 2022.
  • In the last 5 years, Sangamo Therapeutics' Net Cash Flow had a median value of -$8.0 million in 2021 and averaged -$5.6 million.
  • In the last 5 years, Sangamo Therapeutics' Net Cash Flow plummeted by 63308.0% in 2022 and then skyrocketed by 22071.47% in 2024.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Net Cash Flow stood at $2.0 million in 2021, then surged by 150.81% to $5.1 million in 2022, then crashed by 348.34% to -$12.7 million in 2023, then soared by 139.2% to $5.0 million in 2024, then tumbled by 288.52% to -$9.4 million in 2025.
  • Its Net Cash Flow stands at -$9.4 million for Q3 2025, versus $10.4 million for Q2 2025 and -$18.0 million for Q1 2025.